In his role as Radiochemist, Edwin will be instrumental in the development and manufacturing of the medical radioisotope Terbium-161 which is today being adopted for Radioligand Therapy (RLT) on a global scale providing for a novel and promising therapy.
“The therapeutical value of Terbium-161 is extremely potent and will become the next generation of RLT, and I’m therefore proud to be part of the TerThera team dedicated to bringing Tb-161 to the patient,” said Edwin Pietersveld, Radiochemist at TerThera b.v.
